Liver cirrhosis. Edited by J. L. Boyer and L. Bianchi, 465 pp. Lancaster, England: MTP Press, 1987
Charles L. Mendenhall – 1 July 1988
Charles L. Mendenhall – 1 July 1988
Eduard F. Stange, Jürgen Scheibner, Christine Lutz, Hans Ditschuneit – 1 July 1988 – The regulation of bile acid synthesis was studied (i) in intact or colectomized rats receiving cholate or taurocholate as a dietary supplement and (ii) in experiments using chow‐fed animals with a graded intravenous or intraduodenal taurocholate infusion. After the 2‐week diet period a bile fistula was established and rates of taurocholate, tauromuricholate and taurochenodeoxy‐cholate secretion were quantitated by high‐performance liquid chromatography.
Sophie Roy, Gilles Pomier‐Layrargues, Roger F. Butterworth, P.‐Michel Huet – 1 July 1988 – It has been suggested, from studies of a rabbit model of fulminant hepatic failure, that hepatic encephalopathy might be related to an increase in brain γ‐aminobutyric acid uptake through a more permeable blood‐brain barrier, leading to an overactivity of brain γ‐aminobutyric acid‐mediated inhibitory neurotrans‐mission.
Bernard H. Davis, Angelina Vucic – 1 July 1988 – Hepatic sinusoidal fat‐storing Ito cells are felt to represent the primary storage site for hepatic vitamin A and may be important collagen‐producing effector cells during hepatic fibrogenesis. The cirrhotic liver generally has a decreased vitamin A content with increased numbers of “transitional” myofibroblasts adjacent to developing fibrous bands. It has been suggested that Ito cells “transform” into these myofibroblasts.
Anthony J. Stellon, John J. Keating, Philip J. Johnson, Ian G. McFarlane, Roger Williams – 1 July 1988 – Forty‐seven patients with autoimmune chronic active hepatitis in remission on azathioprine and/or prednisolone were entered into a randomized controlled trial to assess the value of azathioprine alone in maintenance of remission.
1 July 1988
D. W. Bullimore – 1 July 1988
Irmin Sternlieb – 1 July 1988 – Experience with liver transplantation for patients with Wilson's disease who have major neurological impairment is limited, and this report describes the results obtained in two such patients. The first was a 30‐year‐old man with a 14‐month history of hepatic and neurological impairment. In spite of treatment with d‐penicillamine, he developed increasing dysarthria, dysphagia, akinesia and rigidity of all four limbs, and required continuous nursing care.
Paul S. Lietman – 1 July 1988
Rebecca W. Van Dyke, Harlan E. Ives – 1 July 1988